Stay updated with breaking news from Davis Jerel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Several analysts have recently updated their ratings and price targets for Chinook Therapeutics (NASDAQ: KDNY): 6/14/2023 – Chinook Therapeutics was downgraded by analysts at Evercore ISI to an “outperform” rating. 6/13/2023 – Chinook Therapeutics was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating. 6/13/2023 – Chinook Therapeutics was downgraded […]
Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Rating) has received a consensus rating of “Hold” from the thirteen research firms that are currently covering the stock, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year target price […]
Bloom Burton cut shares of Chinook Therapeutics (NASDAQ:KDNY – Get Rating) from a buy rating to a hold rating in a report published on Monday, PriceTargets.com reports. Several other research firms have also recently weighed in on KDNY. SVB Securities cut shares of Chinook Therapeutics from an outperform rating to a market perform rating in […]
Cantor Fitzgerald downgraded shares of Chinook Therapeutics (NASDAQ:KDNY – Get Rating) from an overweight rating to a neutral rating in a research report report published on Monday, The Fly reports. Several other research firms have also commented on KDNY. Guggenheim decreased their price objective on shares of Chinook Therapeutics from $43.00 to $35.00 in a […]
Chinook Therapeutics (NASDAQ:KDNY – Get Rating) was downgraded by investment analysts at SVB Securities from an “outperform” rating to a “market perform” rating in a research report issued on Tuesday, The Fly reports. Several other equities analysts have also recently weighed in on KDNY. William Blair cut shares of Chinook Therapeutics from an “outperform” rating […]